Companion Animals

Cat Feline FIP Treatment Access Advanced: Global Equity

Equitable access to FIP antiviral treatment globally is a welfare priority as costs remain prohibitive in many markets.

Key Facts

GS-441524 and molnupiravir are licensed in many high-income countries but not all
Generic versions of FIP antivirals are available in some markets at dramatically lower cost
Treatment courses cost thousands of pounds in markets where only branded drugs are licensed
WHO model essential medicines list inclusion could improve access to FIP antivirals globally

Welfare Considerations

FIP is a treatable disease but treatment cost creates welfare inequity where survival is determined by owner income. Generic drug access and international treatment cost equity would prevent much preventable FIP suffering. Advocacy for essential medicines frameworks that include veterinary antivirals could transform access.

What You Can Do

Support veterinary charitable organisations providing FIP treatment assistance
Advocate for veterinary generic drug licensing frameworks that improve access
Donate to FIP treatment funds that support owners unable to afford branded antivirals